Thalia Therapeutics Plc (AIM:THAT)
London · Delayed Price · Currency is GBP · Price in GBX 0.6100
+0.0350 (6.09%)
Sep 25, 2026, 1:07 PM GMT
Thalia Therapeutics Market Cap
Thalia Therapeutics has a market cap or net worth of 6.95 million as of September 25, 2026. Its market cap has increased by 15.12% in one year.
Market Cap
6.95M
Enterprise Value
5.87M
Revenue
7.26K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.61
ChartMarket Cap Chart
Since May 3, 2017, Thalia Therapeutics's market cap has increased from 4.57M to 6.95M, an increase of 51.95%. That is a compound annual growth rate of 4.55%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 24, 2026 | 6.95M | 58.98% |
| Dec 31, 2025 | 4.37M | 110.82% |
| Dec 31, 2024 | 2.07M | -9.28% |
| Dec 29, 2023 | 2.28M | -47.18% |
| Dec 30, 2022 | 4.32M | -46.33% |
| Dec 31, 2021 | 8.06M | -46.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| May 3, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| SkinBioTherapeutics | 14.90M |
| Fusion Antibodies | 14.02M |
| Palatin Technologies | 13.42M |
| Aptamer Group | 11.23M |
| Genflow Biosciences | 10.62M |
| Solvonis Therapeutics | 7.83M |
| CRISM Therapeutics | 7.72M |
| Cizzle Biotechnology Holdings | 7.01M |